Prognostic Impact of Cell of Origin in Limited-Stage Diffuse Large B-Cell Lymphoma Treated With R-CHOP With or Without Radiation Therapy
Youn, P, Cummings, M.A, Dhakal, S, Burack, W.R, Casulo, C, Barr, P.M, Friedberg, J.W, Constine, L.S
Published in International journal of radiation oncology, biology, physics (01.10.2016)
Published in International journal of radiation oncology, biology, physics (01.10.2016)
Get full text
Journal Article
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
Woyach, Jennifer A, Ruppert, Amy S, Heerema, Nyla A, Zhao, Weiqiang, Booth, Allison M, Ding, Wei, Bartlett, Nancy L, Brander, Danielle M, Barr, Paul M, Rogers, Kerry A, Parikh, Sameer A, Coutre, Steven, Hurria, Arti, Brown, Jennifer R, Lozanski, Gerard, Blachly, James S, Ozer, Hatice G, Major-Elechi, Brittny, Fruth, Briant, Nattam, Sreenivasa, Larson, Richard A, Erba, Harry, Litzow, Mark, Owen, Carolyn, Kuzma, Charles, Abramson, Jeremy S, Little, Richard F, Smith, Scott E, Stone, Richard M, Mandrekar, Sumithra J, Byrd, John C
Published in The New England journal of medicine (27.12.2018)
Published in The New England journal of medicine (27.12.2018)
Get full text
Journal Article
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, John C, Brown, Jennifer R, O'Brien, Susan, Barrientos, Jacqueline C, Kay, Neil E, Reddy, Nishitha M, Coutre, Steven, Tam, Constantine S, Mulligan, Stephen P, Jaeger, Ulrich, Devereux, Steve, Barr, Paul M, Furman, Richard R, Kipps, Thomas J, Cymbalista, Florence, Pocock, Christopher, Thornton, Patrick, Caligaris-Cappio, Federico, Robak, Tadeusz, Delgado, Julio, Schuster, Stephen J, Montillo, Marco, Schuh, Anna, de Vos, Sven, Gill, Devinder, Bloor, Adrian, Dearden, Claire, Moreno, Carol, Jones, Jeffrey J, Chu, Alvina D, Fardis, Maria, McGreivy, Jesse, Clow, Fong, James, Danelle F, Hillmen, Peter
Published in The New England journal of medicine (17.07.2014)
Published in The New England journal of medicine (17.07.2014)
Get full text
Journal Article
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients
Mato, A.R., Hill, B.T., Lamanna, N., Barr, P.M., Ujjani, C.S., Brander, D.M., Howlett, C., Skarbnik, A.P., Cheson, B.D., Zent, C.S., Pu, J.J., Kiselev, P., Foon, K., Lenhart, J., Henick Bachow, S., Winter, A.M., Cruz, A.-L., Claxton, D.F., Goy, A., Daniel, C., Isaac, K., Kennard, K.H., Timlin, C., Fanning, M., Gashonia, L., Yacur, M., Svoboda, J., Schuster, S.J., Nabhan, C.
Published in Annals of oncology (01.05.2017)
Published in Annals of oncology (01.05.2017)
Get full text
Journal Article
Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia
Herman, S E M, Barr, P M, McAuley, E M, Liu, D, Wiestner, A, Friedberg, J W
Published in Leukemia (01.08.2013)
Published in Leukemia (01.08.2013)
Get full text
Journal Article
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma
Evens, A.M., Carson, K.R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P.M., Caimi, P.F., Gregory, S.A., Gordon, L.I.
Published in Annals of oncology (01.12.2013)
Published in Annals of oncology (01.12.2013)
Get full text
Journal Article
NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY FROM THE PHASE 2 CHECKMATE 436 STUDY
Zinzani, P.L., Santoro, A., Gritti, G., Brice, P., Barr, P.M., Kuruvilla, J., Cunningham, D., Kline, J., Johnson, N.A., Mehta‐Shah, N.A., Manley, T., Francis, S., Sharma, M., Moskowitz, A.J.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
FIVE‐YEAR FOLLOW‐UP OF FIRST‐LINE IBRUTINIB FOR TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA//SMALL LYMPHOCYTIC LYMPHOMA
Tedeschi, A., Burger, J., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Lal, I., Dean, J.P., Kipps, T.J.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
HIGH‐RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA ARE NOT ENROLLED ON CLINICAL TRIALS
Reagan, P., Loh, K.P., Baran, A., Hu, J., Casulo, C., Barr, P.M., Friedberg, J.W.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
S107 FIVE‐YEAR FOLLOW‐UP OF PATIENTS RECEIVING IBRUTINIB FOR FIRST‐LINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
Tedeschi, A., Burger, J., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, J., Simpson, D., Offner, F., Moreno, C., Dai, S., Lal, I., Dean, J.P., Kipps, T.J.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
S1601 NIVOLUMAB COMBINED WITH BRENTUXIMAB VEDOTIN FOR RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE 2 CHECKMATE 436 STUDY
Zinzani, P.L., Santoro, A., Gritti, G., Brice, P., Barr, P.M., Kuruvilla, J., Cunningham, D., Kline, J., Johnson, N.A., Mehta‐Shah, N.A., Manley, T., Francis, S., Sharma, M., Moskowitz, A.J.
Published in HemaSphere (01.06.2019)
Published in HemaSphere (01.06.2019)
Get full text
Journal Article
Corrections to “A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma”
Evens, A.M., Carson, K.R., Kolesar, J., Nabhan, C., Helenowski, I., Islam, N., Jovanovic, B., Barr, P.M., Caimi, P.F., Gregory, S.A., Gordon, L.I.
Published in Annals of oncology (01.07.2014)
Published in Annals of oncology (01.07.2014)
Get full text
Journal Article
A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRALISIB IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WHO ARE INTOLERANT TO PRIOR BTK OR PI3K DELTA INHIBITOR THERAPY
Mato, A.R., Schuster, S.J., Lamanna, N., Pagel, J.M., Flinn, I.W., Barrientos, J., Reeves, J.A., Cheson, B.D., Barr, P.M., Kambhampati, S., Lansigan, F., Pu, J.J., Skarbnik, A., Fonseca, G., Dorsey, C., LaRatta, N.M., Weissbrot, H., Svoboda, J., Luning Prak, E.T., Tsao, P., Sitlinger, A., Paskalis, D., Sportelli, P., Miskin, H.P., Weiss, M.S., Brander, D.M.
Published in Hematological oncology (01.06.2019)
Published in Hematological oncology (01.06.2019)
Get full text
Journal Article
A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 G Y INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK H ODGKIN LYMPHOMA
Kumar, A., Casulo, C., Advani, R., Budde, E., Barr, P.M., Batlevi, C.L., Chen, R., Constine, L.S., Courtien, A.I., Dandapani, S.V., Drullinsky, P., Friedberg, J.W., Hamlin, P.A., Hoppe, R.T., Matasar, M.J., McArthur, G.N., Miller, S.T., Moskowitz, A.J., Noy, A., Schoder, H., Straus, D.J., Yang, J., Younes, A., Zelenetz, A.D., Yahalom, J., Moskowitz, C.H.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA
Kumar, A., Casulo, C., Advani, R., Budde, E., Barr, P.M., Batlevi, C.L., Chen, R., Constine, L.S., Courtien, A.I., Dandapani, S.V., Drullinsky, P., Friedberg, J.W., Hamlin, P.A., Hoppe, R.T., Matasar, M.J., McArthur, G.N., Miller, S.T., Moskowitz, A.J., Noy, A., Schoder, H., Straus, D.J., Yang, J., Younes, A., Zelenetz, A.D., Yahalom, J., Moskowitz, C.H.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
EFFECT OF SINGLE‐AGENT IBRUTINIB ON TUMOR DEBULKING AND REDUCTIONS IN TUMOR LYSIS SYNDROME (TLS) RISK IN PATIENTS (PTS) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Tam, C.S., Byrd, J.C., O'Brien, S., Coutre, S., Barr, P.M., Furman, R.R., Kipps, T.J., Burger, J.A., Stevens, D., Sharman, J., Ghia, P., Flinn, I., Zhou, C., Ninomoto, J., James, D.F., Wierda, W.G.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
INTEGRATED ANALYSIS: OUTCOMES OF IBRUTINIB‐TREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LEUKEMIA (CLL/SLL) WITH HIGH‐RISK PROGNOSTIC FACTORS
Kipps, T.J., Fraser, G., Coutre, S.E., Brown, J.R., Barrientos, J.C., Barr, P.M., Byrd, J.C., O'Brien, S.M., Dilhuydy, M., Hillmen, P., Jaeger, U., Moreno, C., Cramer, P., Stilgenbauer, S., Chanan‐Khan, A.A., Mahler, M., Salman, M., Cheng, M., Londhe, A., Ninomoto, J., Howes, A., James, D.F., Hallek, M.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
LONG‐TERM EFFICACY AND SAFETY IN THE RESONATE STUDY: IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) WITH UP TO FOUR YEARS FOLLOW‐UP
Montillo, M., Byrd, J.C., Hillmen, P., O'Brien, S., Barrientos, J.C., Reddy, N.M., Coutre, S., Tam, C.S., Mulligan, S.P., Jaeger, U., Barr, P.M., Furman, R.R., Kipps, T.J., Thornton, P., Moreno, C., Pagel, J.M., Burger, J.A., Jones, J., Dai, S., Vezan, R., James, D.F., Brown, J.R.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article
THE 23‐GENE GENE EXPRESSION‐BASED ASSAY DOES NOT PREDICT INTERIM PET SCAN RESULTS AFTER ABVD IN ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA IN THE US INTERGROUP S0816 TRIAL
Scott, D.W., Li, H., Harvey, Y., Chan, F., Mottok, A., Boyle, M., Evens, A.M., Schoder, H., Straus, D.J., Bartlett, N.L., Sweetenham, J.W., Barr, P.M., Fanale, M.A., Hsi, E.D., Cook, J.R., Kahl, B.S., Leonard, J.P., Friedberg, J.W., Leblanc, M., Steidl, C., Gascoyne, R.D., Rimsza, L.M., Press, O.W.
Published in Hematological oncology (01.06.2017)
Published in Hematological oncology (01.06.2017)
Get full text
Journal Article